Miller Anestesia

430 / 2894

123. Hoet P, Graf ML, Bourdi M, et al: Epidemic of liver
disease caused by hydrochlorofluorocarbons used as
ozone-sparing substitutes of chlorofluorocarbons.
Lancet 350:556–559, 1997.
124. Joshi PH, Conn HO: The syndrome of methoxyflu-
rane-associated hepatitis. Ann Intern Med 80:395–
401, 1974.
125. Martin JL: Halothane hepatitis: A possible immune-
mediated hepatitis. In Newcombe DS, Rose NR,
Bloom JC (eds): Clinical Immunotoxicology. New
York, Raven Press, 1992, pp 155–175.
126. Kenna JG, Neuberger J, Williams R: Specific antibo-
dies to halothane-induced liver antigens in halo­
thane-associated hepatitis.Br JAnaesth 59:1286–1290,
1987.
127. Nomura F, Hatano H, Ohnishi K, et al: Effects of
anticonvulsant agents on halothane-induced liver
injury in human subjects and experimental animals.
Hepatology 6:952–956, 1986.
128. Hubbard AK, Roth AK, Gandolfi AJ, et al: Halo-
thane hepatitis patients generate an antibody res-
ponse toward a covalently bound metabolite of
halothane. Anesthesiology 68:791–796, 1988.
129. Martin JL, Kenna JG, Pohl LR: Antibody assays for
the detection of patients sensitized to halothane.
Anesth Analg 70:154–159, 1990.
130. Njoku D: Effects of halogenated inhalation agents
on the liver and kidneys. Probl Anesth Curr Issues
Pediatr Anesth 10:478–487, 2000.
131. Kharasch ED, Hankins DC, Thummel KE: Human
kidney methoxyflurane and sevoflurane metabo-
lism. Intrarenal fluoride production as a possible
mechanism of methoxyflurane nephrotoxicity.
Anesthesiology 82:689–699, 1995.
132. Mazze RI, Cousins MJ, Barr GA: Renal effects and
metabolism of isoflurane in man. Anesthesiology
40:536–542, 1974.
133. Arnold JH, Truog RD, Rice SA: Prolonged adminis-
tration of isoflurane to pediatric patients during
mechanical ventilation. Anesth Analg 76:520–526,
1993.
134. Kobayashi Y, Ochiai R, Takeda J, et al: Serum and
urinary inorganic fluoride concentrations after pro-
longed inhalation of sevoflurane in humans.Anesth
Analg 74:753–757, 1992.
135. Nuscheler M, Conzen P, Peter K: [Sevoflurane:
Metabolism and toxicity]. Anaesthesist 47(Suppl
1):S24–S32, 1998.
136. Truog RD, Rice SA: Inorganic fluoride and prolon-
ged isoflurane anesthesia in the intensive care unit.
Anesth Analg 69:843–845, 1989.
137. Hara T, Fukusaki M, Nakamura T, Sumikawa K:
Renal function in patients during and after hypo-
tensive anesthesia with sevoflurane. J Clin Anesth
10:539–545, 1998.
138. Frink EJ Jr, Malan TP, Isner J, et al: Renal concen-
trating function with prolonged sevoflurane or
enflurane anesthesia in volunteers. Anesthesiology
80:1019–1025, 1994.
139. Higuchi H, Arimura S, Sumikura H, et al: Urine
concentrating ability after prolonged sevoflurane
anaesthesia. Br J Anaesth 73:239–240, 1994.
140. Groudine SB, Fragen RJ, Kharasch ED, et al: Com-
parison of renal function following anesthesia with
low-flow sevoflurane and isoflurane. J Clin Anesth
11:201–207, 1999.
141. Bito H, Ikeda K: Long-duration, low-flow sevo-
flurane anesthesia using two carbon dioxide
absorbents. Quantification of degradation pro-
ducts in the circuit. Anesthesiology 81:340–345,
1994.
142. Morio M, Fujii K, Satoh N, et al: Reaction of sevo-
flurane and its degradation products with soda lime.
Toxicity of the byproducts.Anesthesiology 77:1155–
1164, 1992.
143. Artu A: Renal effects of sevoflurane during condi-
tions of possible increased risk. J Clin Anesth
10:531–538, 1998.
144. Mori N, Nagata H, Ohta S, Suzuki M: Prolonged
sevoflurane inhalation was not nephrotoxic in two
patients with refractory status asthmaticus. Anesth
Analg 83:189–191, 1996.
145. Conzen PF, Nuscheler M, Melotte A, et al: Renal
function and serum fluoride concentrations in
patients with stable renal insufficiency after anes-
thesia with sevoflurane or enflurane. Anesth Analg
81:569–575, 1995.
146. Tsukamoto N, Hirabayashi Y, Shimizu R, Mitsuhata
H: The effects of sevoflurane and isoflurane anesthe-
sia on renal tubular function in patients with mode-
rately impaired renal function. Anesth Analg 82:
909–913, 1996.
147. Morita K, Otsuka F, Ogura T, et al: Sevoflurane
anaesthesia causes a transient decrease in aquapo-
rin-2 and impairment of urine concentration. Br J
Anaesth 83:734–739, 1999.
148. Smiley RM, Ornstein E, Pantuck EJ, et al: Metabo-
lism of desflurane and isoflurane to fluoride ion in
surgical patients. Can J Anaesth 38:965–968, 1991.
149. Bito H, Ikeda K: Closed-circuit anesthesia with
sevoflurane in humans. Effects on renal and hepatic
function and concentrations of breakdown products
with soda lime in the circuit.Anesthesiology 80:71–
76, 1994.
150. Cunningham DD, Huang S, Webster J, et al: Sevo-
flurane degradation to compound A in anaesthesia
breathing systems. Br J Anaesth 77:537–543, 1996.
151. Bito H, Ikeda K: Degradation products of sevoflu-
rane during low-flow anaesthesia. Br J Anaesth
74:56–59, 1995.
152. Gonsowski CT, Laster MJ, Eger EI, et al: Toxicity of
compound A in rats. Effect of a 3-hour administra-
tion. Anesthesiology 80:556–565, 1994.
153. Keller KA, Callan C, Prokocimer P, et al: Inhalation
toxicity study of a haloalkene degradant of sevoflu-
rane, compound A (PIFE), in Sprague-Dawley rats.
Anesthesiology 83:1220–1232, 1995.
154. Gonsowski CT, Laster MJ, Eger EI, et al: Toxicity of
compound A in rats. Effect of increasing duration of
administration. Anesthesiology 80:566–573, 1994.
155. Bito H, Ikeda K: Plasma inorganic fluoride and
intracircuit degradation product concentrations in
long-duration, low-flow sevoflurane anesthesia.
Anesth Analg 79:946–951, 1994.
156. Frink EJ Jr, Isner RJ, Malan TP Jr, et al: Sevoflurane
degradation product concentrations with soda lime
during prolonged anesthesia. J Clin Anesth 6:239–
242, 1994.
157. Bito H, Ikeda K: Renal and hepatic function in sur-
gical patients after low-flow sevoflurane or isoflu-
rane anesthesia. Anesth Analg 82:173–176, 1996.
158. Mazze RI, Callan CM, Galvez ST, et al: The effects
of sevoflurane on serum creatinine and blood urea
nitrogen concentrations: A retrospective, twenty-
two–center, comparative evaluation of renal
function in adult surgical patients. Anesth Analg
90:683–688, 2000.
159. Kharasch ED, Frink EJ Jr, Artru A, et al: Long-
duration low-flow sevoflurane and isoflurane effects
on postoperative renal and hepatic function.Anesth
Analg 93:1511–1520, 2001.
160. Mazze RI, Jamison RL: Low-flow (1l/min) sevoflu-
rane: Is it safe? Anesthesiology 86:1225–1227, 1997.
161. Kumano H, Osaka S, Ishimura N, Nishiwada M:
[Effects of enflurane, isoflurane, and sevoflurane on
renal tubular functions]. Masui 41:1735–1740,
1992.
162. Bito H, Ikeuchi Y, Ikeda K: Effects of low-flow sevo-
flurane anesthesia on renal function: Comparison
with high-flow sevoflurane anesthesia and low-flow
isoflurane anesthesia. Anesthesiology 86:1231–
1237, 1997.
163. Kharasch ED, Frink EJ Jr, Zager R, et al: Assessment
of low-flow sevoflurane and isoflurane effects on
renal function using sensitive markers of tubular
toxicity. Anesthesiology 86:1238–1253, 1997.
164. Nishiyama T, Hanaoka K: Inorganic fluoride kine-
tics and renal and hepatic function after repeated
sevoflurane anesthesia. Anesth Analg 87:468–473,
1998.
165. Eger EI 2nd, Koblin DD, Rowland T, et al: Nephro-
toxicity of sevoflurane versus desflurane anesthesia
in volunteers. Anesth Analg 84:160–168, 1997.
166. Ebert TJ, Frink EJ Jr, Kharasch ED: Absence of bio-
chemical evidence for renal and hepatic dysfunction
after 8 hours of 1.25 minimum alveolar concentra-
tion sevoflurane anesthesia in volunteers. Anesthe-
siology 88:601–610, 1998.
167. Goldberg ME, Cantillo J, Gratz I, et al: Dose of
compound A, not sevoflurane, determines changes
in the biochemical markers of renal injury in healthy
volunteers. Anesth Analg 88:437–445, 1999.
168. Higuchi H, Wada H, Usui Y, et al: Effects of probe-
necid on renal function in surgical patients anesthe-
tized with low-flow sevoflurane. Anesthesiology
94:21–31, 2001.
169. Higuchi H, Sumita S, Wada H, et al: Effects of sevo-
flurane and isoflurane on renal function and on
possible markers of nephrotoxicity. Anesthesiology
89:307–322, 1998.
170. Eger EI, 2nd, Gong D, Koblin DD, et al: Dose-rela-
ted biochemical markers of renal injury after sevo-
flurane versus desflurane anesthesia in volunteers.
Anesth Analg 85:1154–1163, 1997.
171. Ebert TJ, Messana LD, Uhrich TD, Staacke TS:
Absence of renal and hepatic toxicity after four
hours of 1.25 minimum alveolar anesthetic concen-
tration sevoflurane anesthesia in volunteers. Anesth
Analg 86:662–667, 1998.
172. Levine MF, Sarner J, Lerman J, et al: Plasma inorga-
nic fluoride concentrations after sevoflurane
anesthesia in children. Anesthesiology 84:348–353,
1996.
173. Frink EJ Jr, Green WB Jr, Brown EA, et al: Com-
pound A concentrations during sevoflurane anes-
thesia in children. Anesthesiology 84:566–571,
1996.
174. Payne AK, Morgan SE, Gandolfi AJ, Brendel K: Bio-
transformation of sevoflurane by rat neonate liver
slices. Drug Metab Dispos 23:497–500, 1995.
175. Iyer RA, Anders MW: Cysteine conjugate beta-
lyase–dependent biotransformation of the cysteine
S-conjugates of the sevoflurane degradation product
compound A in human, nonhuman primate, and rat
kidney cytosol and mitochondria. Anesthesiology
85:1454–1461, 1996.
176. Spracklin DK, Kharasch ED: Evidence for metabo-
lism of fluoromethyl 2,2-difluoro-1-(trifluoro­
methyl)vinyl ether (compound A), a sevoflurane
degradation product, by cysteine conjugate
beta-lyase. Chem Res Toxicol 9:696–702,
1996.
177. Jin L, Baillie TA, Davis MR, Kharasch ED: Nephro-
toxicity of sevoflurane compound A (fluoromethyl-
2,2-difluoro-1-(trifluoromethyl)vinyl ether) in rats:
Evidence for glutathione and cysteine conjugate
formation and the role of renal cysteine conjugate
beta-lyase. Biochem Biophys Res Commun
210:498–506, 1995.
178. Jin L, Davis MR, Kharasch ED, et al: Identification
in rat bile of glutathione conjugates of fluoromethyl
2,2-difluoro-1-(trifluoromethyl)vinylether,anephro­
toxic degradate of the anesthetic agent sevoflurane.
Chem Res Toxicol 9:555–561, 1996.
179. Commandeur JN, Oostendorp RA, Schoofs PR, et
al: Nephrotoxicity and hepatotoxicity of 1,1-dichlo­
ro-2,2-difluoroethylene in the rat. Indications for
differential mechanisms of bioactivation. Biochem
Pharmacol 36:4229–4237, 1987.
180. Vamvakas S, Kremling E, Dekant W: Metabolic acti-
vation of the nephrotoxic haloalkene 1,1,2-tri-
chloro-3,3,3-trifluoro-1-propene by glutathione
conjugation. Biochem Pharmacol 38:2297–2304,
1989.
430 Farmacología y anestesia II